
FACSIMILE TRANSMITTAL SHEET

To:	From:
Examiner Simon Oh	Guy Donatiello
FAX NUMBER:	Date:
703-746-7644	August 27, 2003
COMPANY:	TOTAL NO. OF PAGES INCLUDING COVER:
United States Patent and Trademark Office	3
PHONE NUMBER:	SENDER'S REFERENCE NUMBER:
703-305-3265	1203-01
Re:	YOUR REFERENCE NUMBER:
Proposed Amendment	10/045,341

URGENT FOR REVIEW PLEASE COMMENT PLEASE REPLY PLEASE RECYCLE

NOTES/COMMENTS:

The change is not extensive, but it is consistent with what we discussed. Please call to discuss this.

Thank You for all your help.

Guy Donatiello

Guy Donatiello
Senior Patent Counsel
Endo Pharmaceuticals Inc.
100 Painters Drive
Chadds Ford, PA 19317
610-558-9800 x4275
Direct Fax: 484-840-4269
donatiello.guy@endo.com

Amendments to the Claims

Please amend claims 1 and 11 as shown below.

1. (Currently Amended) A method for treating non-neuropathic pain comprising topically administering a composition containing 4-6% lidocaine to a patient near a pain locus in an amount sufficient to produce analgesia without causing anesthesia wherein said composition is incorporated into a topical patch for application to skin.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Original) The method of claim 1 wherein said non-neuropathic pain to be treated results from a soft-tissue injury.

9. (Original) The method of claim 8, wherein said soft-tissue injury is selected from the group consisting of pain associated with ligaments, tendons, muscles, bursa, sprains, strains, inflammations, contusions, arthritises, and post-surgical pains.

10. (Previously Amended) The method of claim 1 wherein said non-neuropathic pain is derived from one or more conditions selected from the group consisting of myofascial pains, fibromyalgia, bursitis, costochondritis, repetitive motion injuries, carpal tunnel syndrome, and nociceptive pain.

11. (Currently Amended) A method for treating non-neuropathic pain comprising the step of:

topically administering a [transdermal] patch containing a pharmaceutical composition consisting of 5% lidocaine as the only active ingredient, and the remainder consisting of inactive pharmaceutically acceptable materials.

12. (Previously Added) A method for treating non-neuropathic pain comprising topically administering a composition containing 4-6% lidocaine as the only active ingredient to a patient near a pain locus in an amount sufficient to produce analgesia without causing anesthesia.

13. (Previously Added) The method of claim 12 wherein said non-neuropathic pain is derived from one or more conditions selected from the group consisting of myofascial pains, fibromyalgia, bursitis, costochondritis, repetitive motion injuries, carpal tunnel syndrome, and nociceptive pain.

14. (Previously Added) The method of claim 12 wherein said non-neuropathic pain to be treated results from a soft-tissue injury.

15. (Previously Added) The method of claim 14, wherein said soft-tissue injury is selected from the group consisting of pain associated with ligaments, tendons, muscles, bursa, sprains, strains, inflammations, contusions, arthritises, and post-surgical pains.